Shattuck Labs (STTK)

• Market cap: $57.3M
• 1 day: 3.45%
• 5 days: -6.25%
• 1 month: -12.41%
• 3 months: 9.09%
• 6 months: -67.03%
• Year to date: -0.83%
• 1 year: -87.90%
• 5 years: -93.80%
• 10 years: -93.80%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Employees: 75

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

4% less funds holding

Funds holding: 77 [Q3] → 74 (-3) [Q4]

9.83% less ownership

Funds ownership: 75.92% [Q3] → 66.09% (-9.83%) [Q4]

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

69% less capital invested

Capital invested by funds: $125M [Q3] → $38.2M (-$86.4M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 233% upside
• Avg. target: $4 233% upside
• High target: $4 233% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Leerink Partners Faisal Khurshid 25% 1-year accuracy 3 / 12 met price target

233% upside $4

Outperform Initiated

17 Mar 2025